Figure 2. Prevalence of lipid abnormalities before and after treatment with lipid modifying therapy in high-risk patients (n=2,016)

At Baseline

- Low HDL-C (44%, n=888)
  - Elevated LDL-C (92.6%, n=1,867)
  - Elevated TG (66.4%, n=1,338)
  - 2.2% (n=45)
  - 3.6% (n=73)
  - 30.0% (n=606)
  - 24.4% (n=492)

At Follow-up

- Low HDL-C (37.7%, n=760)
  - Elevated LDL-C (62.7%, n=1,264)
  - Elevated TG (53.1%, n=1,070)
  - 4.4% (n=89)
  - 8.2% (n=165)

No lipid disorder 13.1% (n=264)

HDL-C = High-Density Lipoprotein
LDL-C = Low-Density Lipoprotein
TG = Triglycerides.